Loading...
In a recent meta-analysis, rosiglitazone was associated with increased risk for myocardial infarction and possibly cardiovascular mortality (Journal Watch May 24 2007). The authors noted that the industry-sponsored RECORD trial, specifically designed to examine cardiovascular outcomes associated with rosiglitazone, was still in progress. Because of the controversy sparked by the meta-analysis, the RECORD investigators conducted this interim analysis (about two thirds of the way through the trial).
Researchers in Europe and Australasia enrolled 4447 type 2 diabetic patients taking metformin or sulfonylurea monotherapy. Half the patients were randomized to receive add-on rosiglitazone; in the control group, metformin users received add-on sulf…